Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Discharge protocol in acute pancreatitis, an international survey and cohort analysis

  • Nagy, Rita
  • Ocskay, Klementina
  • Sipos, Zoltán
  • Szentesi, Andrea
  • Vincze, Áron
  • Czakó, László
  • Izbéki, Ferenc
  • Shirinskaya, Natalia V.
  • Poluektov, Vladimir L.
  • Zolotov, Alexandr N.
  • Zhu, Yin
  • Xia, Liang
  • He, Wenhua
  • Sutton, Robert
  • Szatmary, Peter
  • Mukherjee, Rajarshi
  • Burridge, Isobel Saffron
  • Wauchope, Emma
  • Francisco, Elsa
  • Aparicio Alarcón, David|||0000-0002-1971-5335
  • Pinto, Bruno
  • Gomes, António
  • Nunes, Vitor
  • Tantau, Vasile Marcel
  • Sagau, Emanuela Denisa
  • Tantau, Alina Ioana
  • Suceveanu, Andra Iulia
  • Tocia, Cristina
  • Dumitru, Andrei
  • Pando, Elizabeth|||0000-0001-6898-5502
  • Alberti Delgado, Piero Arturo|||0000-0003-3512-0814
  • Cirera de Tudela, Arturo|||0000-0002-4972-5315
  • Molero, Xavier|||0000-0003-2473-7405
  • Lee, Hong Sik
  • Jung, Min Kyu
  • Kim, Eui Joo
  • Lee, Sanghyub
  • Rebollo, María Lourdes Ruiz
  • Nistal, Reyes Busta
  • Santervas, Sandra Izquierdo
  • Lesko, Dusan
  • Soltes, Marek
  • Radoňák, Jozef
  • Zatorski, Hubert
  • Małecka-Panas, Ewa
  • Fabisiak, Adam
  • Yaroslav, M. Susak
  • Mykhailo, V. Maksymenko
  • Olekcandr, A. Tkachenko
  • Barauskas, Giedrius
  • Simanaitis, Vytautas
  • Ignatavicius, Povilas
  • Jinga, Mariana
  • Balaban, Vasile-Daniel
  • Patoni, Cristina
  • Gong, Liang
  • Song, Kai
  • Li, Yunlong
  • Gonçalves, T. Cúrdia
  • Freitas, Marta
  • Macedo, Vítor
  • Vornhuelz, Marlies
  • Klauss, Sarah
  • Beyer, Georg
  • Koksal, Aydin Seref
  • Tozlu, Mukaddes
  • Eminler, Ahmet Tarik
  • Torres Monclús, Nuria
  • Pijoan Comas, Eva
  • Rodríguez-Oballe, Juan Armando|||0000-0002-9838-764X
  • Nawacki, Łukasz
  • Głuszek, Stanisław
  • Rama-Fernández, Alberto
  • Galego, Marco
  • de la Iglesia, Daniel
  • Aykut, Umut Emre
  • Duman, Deniz Güney
  • Aslan, Rahmi
  • Gherbon, Adriana
  • Deng, Lihui
  • Huang, Wei
  • Xia, Qing
  • Poropat, Goran
  • Radovan, Anja
  • Vranić, Luka
  • Ricci, Claudio
  • Ingaldi, Carlo
  • Casadei, Riccardo
  • Negoi, Ionut
  • Ciubotaru, Cezar
  • Iordache, Florin Mihail
  • Constantinescu, Gabriel
  • Sandru, Vasile
  • Altintas, Engin
  • Balci, Hatice Rizaoglu
  • Constantino, Júlio
  • Aveiro, Débora
  • Pereira, Jorge
  • Gunay, Suleyman
  • Misirlioglu Sucan, Seda
  • Dronov, Oleksiy
  • Kovalska, Inna
  • Bush, Nikhil
  • Rana, Surinder Singh
  • Chooklin, Serge
  • Chuklin, Serhii
  • Saizu, Ionut Adrian
  • Gheorghe, Cristian
  • Göltl, Philipp
  • Hirth, Michael
  • Mateescu, Radu Bogdan
  • Papuc, Geanina
  • Minkov, Georgi Angelov
  • Enchev, Emil Tihomirov
  • Mastrangelo, Laura
  • Jovine, Elio
  • Chen, Weiwei
  • Zhu, Quping
  • Gąsiorowska, Anita
  • Fabisiak, Natalia
  • Bezmarevic, Mihailo
  • Litvin, Andrey
  • Mottes, Martina Cattani
  • Choi, Eun Kwang
  • Bánovčin, Peter
  • Nosáková, Lenka
  • Kovacheva-Slavova, Mila Dimitrova
  • Kchaou, Ali
  • Tlili, Ahmed
  • Marino, Marco V.
  • Kusnierz, Katarzyna
  • Mickevicius, Artautas
  • Hollenbach, Marcus
  • Molcan, Pavol
  • Ioannidis, Orestis|||0000-0002-0861-8783
  • Tokarev, Mark Valerievich
  • Ince, Ali Tüzün
  • Semenenko, Ivan Albertovich
  • Galeev, Shamil
  • Ramírez Maldonado, Elena|||0000-0001-9213-7212
  • Sallinen, Ville
  • Pencik, Petr
  • Bajor, Judit
  • Sarlós, Patrícia
  • Hágendorn, Roland
  • Gódi, Szilárd
  • Szabó, Imre
  • Czimmer, József
  • Pár, Gabriella
  • Illés, Anita
  • Faluhelyi, Nándor
  • Kanizsai, Péter
  • Nagy, Tamás
  • Mikó, Alexandra
  • Németh, Balázs
  • Hamvas, József
  • Bod, Barnabás
  • Varga, Márta
  • Török, Imola
  • Novák, János
  • Patai, Árpád
  • Sümegi, János
  • Góg, Csaba
  • Papp, Mária
  • Erőss, Bálint
  • Váncsa, Szilárd
  • Teutsch, Brigitta
  • Márta, Katalin
  • Hegyi, Péter Jenő
  • Tornai, Tamás
  • Lázár, Balázs
  • Hussein, Tamás
  • Tarján, Dorottya
  • Lipp, Mónika
  • Kovács, Beáta
  • Urbán, Orsolya
  • Fürst, Emese
  • Tari, Edina
  • Kocsis, Ibolya
  • Maurovich-Horvát, Pál
  • Tihanyi, Balázs
  • Eperjesi, Orsolya
  • Kormos, Zita
  • Deák, Pál Ákos
  • Párniczky, Andrea
  • Hegyi, Péter
There are several overlapping clinical practice guidelines in acute pancreatitis (AP), however, none of them contains suggestions on patient discharge. The Hungarian Pancreatic Study Group (HPSG) has recently developed a laboratory data and symptom-based discharge protocol which needs to be validated. (1) A survey was conducted involving all members of the International Association of Pancreatology (IAP) to understand the characteristics of international discharge protocols. (2) We investigated the safety and effectiveness of the HPSG-discharge protocol. According to our international survey, 87.5% (49/56) of the centres had no discharge protocol. Patients discharged based on protocols have a significantly shorter median length of hospitalization (LOH) (7 (5;10) days vs. 8 (5;12) days) p < 0.001), and a lower rate of readmission due to recurrent AP episodes (p = 0.005). There was no difference in median discharge CRP level among the international cohorts (p = 0.586). HPSG-protocol resulted in the shortest LOH (6 (5;9) days) and highest median CRP (35.40 (13.78; 68.40) mg/l). Safety was confirmed by the low rate of readmittance (n = 35; 5%). Discharge protocol is necessary in AP. The discharge protocol used in this study is the first clinically proven protocol. Developing and testifying further protocols are needed to better standardize patients' care.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

GATA2 deficiency and MDS/AML: experimental strategies for disease modelling and future therapeutic prospects

  • Kotmayer, Lili
  • Romero-Moya, Damià
  • Marin-Bejar, Oskar
  • Kozyra, Emilia
  • Català, Albert
  • Bigas Salvans, Anna
  • Wlodarski, Marcin W.
  • Bödör, Csaba
  • Giorgetti, Alessandra
The importance of predisposition to leukaemia in clinical practice is being increasingly recognized. This is emphasized by the establishment of a novel WHO disease category in 2016 called "myeloid neoplasms with germline predisposition". A major syndrome within this group is GATA2 deficiency, a heterogeneous immunodeficiency syndrome with a very high lifetime risk to develop myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). GATA2 deficiency has been identified as the most common hereditary cause of MDS in adolescents with monosomy 7. Allogenic haematopoietic stem cell transplantation is the only curative option; however, chances of survival decrease with progression of immunodeficiency and MDS evolution. Penetrance and expressivity within families carrying GATA2 mutations is often variable, suggesting that co-operating extrinsic events are required to trigger the disease. Predictive tools are lacking, and intrafamilial heterogeneity is poorly understood; hence there is a clear unmet medical need. On behalf of the ERAPerMed GATA2 HuMo consortium, in this review we describe the genetic, clinical, and biological aspects of familial GATA2-related MDS, highlighting the importance of developing robust disease preclinical models to improve early detection and clinical decision-making of GATA2 carriers., This work was supported by ERA PerMed GATA2-HuMo Funding Mechanism (Spain: Acció instrumental de SLT011/18/00006 of the Department of Health of the Government of Catalonia, to AG and AB; Hungary: ED-18-1-2019-001 grant from the National Research, Development and Innovation Office to CB; and Germany: German Federal Ministry of Education and Research (BMBF) 2018-123/01KU1904 to MWW), ÚNKP-21-2-I-SE-21 and Hungarian National Academy of Scientist Education grant to KL, TKP2021-NVA-15, TKP2021-EGA-24 and EU's Horizon 2020 research and innovation programme under grant agreement no. 739593 and Elixir Hungary to CB, MSCA No 101029927-scGATA2track (H2020-MSCA-IF-2020) to OM-B, the Spanish Ministry of Economy, Industry, and Competitiveness (MINECO PID2020-15591RB-100), La Marató de TV3 (202001-32), FPS Grant 2018 by Fondazione Pisana per la Scienza ONLUS and CERCA Programme/Generalitat de Catalunya for institutional support to AG, Vera and Joseph Dresner Foundation, Evans MDS Foundation, American Lebanese Syrian Associated Charities, and BMBF MyPred 01GM1911A to MWW. Open access funding enabled and organized by ProjektDEAL.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: A study by ERIC in HARMONY

  • Mansouri, Larry
  • Espinet Solà, Blanca
  • Rosenquist, Richard
Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status. In this study, we assessed the impact of nine recurrently mutated genes (BIRC3, EGR2, MYD88, NFKBIE, NOTCH1, POT1, SF3B1, TP53, and XPO1) in pre-treatment samples from 4580 patients with CLL, using time-to-first-treatment (TTFT) as the primary end-point in relation to IGHV gene SHM status. Mutations were detected in 1588 (34.7%) patients at frequencies ranging from 2.3-9.8% with mutations in NOTCH1 being the most frequent. In both univariate and multivariate analyses, mutations in all genes except MYD88 were associated with a significantly shorter TTFT. In multivariate analysis of Binet stage A patients, performed separately for IGHV-mutated (M-CLL) and unmutated CLL (U-CLL), a different spectrum of gene alterations independently predicted short TTFT within the two subgroups. While SF3B1 and XPO1 mutations were independent prognostic variables in both U-CLL and M-CLL, TP53, BIRC3 and EGR2 aberrations were significant predictors only in U-CLL, and NOTCH1 and NFKBIE only in M-CLL. Our findings underscore the need for a compartmentalized approach to identify high-risk patients, particularly among M-CLL patients, with potential implications for stratified management., The European Research Initiative on CLL (ERIC) is a partner in the HARMONY Alliance, the EHA Scientific Working group on CLL and the ELN Workpackage 7 on CLL. This work was in part supported by; Associazione Italiana per la Ricerca sul Cancro—AIRC, Milano, Italy (Investigator Grant #20246 and Special Program on Metastatic Disease—5 per mille #21198); ERA NET TRANSCAN-2 Joint Transnational Call for Proposals: JTC 2014 (project #143 GCH-CLL) and JTC 2016 (project #179 NOVEL), project code (MIS) 5041673; Bando della Ricerca Finalizzata 2018, Ministero della Salute, Roma, Italy (progetto RF-2018–12368231); “la Caixa” Foundation (Health Research 2017 Program HR17-00221); the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245), and the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_TATA_21_3223); the Hellenic Precision Medicine Network in Oncology; project ODYSSEAS (Intelligent and Automated Systems for enabling the Design, Simulation and Development of Integrated Processes and Products) implemented under the “Action for the Strategic Development on the Research and Technological Sector”, funded by the Operational Programme “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020) and co-financed by Greece and the European Union, with grant agreement no: MIS 5002462”; MH CZ—DRO (FNBr, 65269705), NV19-03-00091 and the project National Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102)—Funded by the European Union—Next-Generation EU; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co-funded by the European Union; the EU’s Horizon 2020 research and innovation program under grant agreement No. 739593, by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the K21_137948, FK20_134253, TKP2021-EGA-24 and TKP2021-NVA-15 funding schemes, and Elixir Hungary; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co-funded by the European Union; Fondo di Ateneo per la Ricerca (FAR) 2019, 2020 and 2021 of the University of Ferrara (GMR; AC), Associazione Italiana contro le Leucemie-Linfomi e Mieloma ONLUS Ferrara (AC; GMR), BEAT Leukemia Foundation Milan Italy (AC); the Danish Cancer Society and the CLL-CLUE project under the frame of ERA PerMed; Cancer Research UK (ECRIN-M3 accelerator award C42023/A29370, Southampton Experimental Cancer Medicine Centre grant C24563/A15581, Cancer Research UK Southampton Centre grant C34999/A18087, and programme C2750/A23669); the Swedish Cancer Society (19 0425 Pj 01 H), the Swedish Research Council (2020-01750), the Knut and Alice Wallenberg Foundation (2016.0373), Region Stockholm (ALF/FoUI-962423), and Radiumhemmets Forskningsfonder (194133), Stockholm; and Lion’s Cancer Research Foundation, Uppsala.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

GATA2 deficiency and MDS/AML: experimental strategies for disease modelling and future therapeutic prospects

  • Kotmayer, Lili
  • Romero Moya, Damià
  • Marin-Bejar, Oskar
  • Kozyra, Emilia
  • Català, Albert
  • Bigas Salvans, Anna
  • Wlodarski, Marcin W
  • Bödör, Csaba
  • Giorgetti, Alessandra
The importance of predisposition to leukaemia in clinical practice is being increasingly recognized. This is emphasized by the establishment of a novel WHO disease category in 2016 called 'myeloid neoplasms with germline predisposition'. A major syndrome within this group is GATA2 deficiency, a heterogeneous immunodeficiency syndrome with a very high lifetime risk to develop myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). GATA2 deficiency has been identified as the most common hereditary cause of MDS in adolescents with monosomy 7. Allogenic haematopoietic stem cell transplantation is the only curative option; however, chances of survival decrease with progression of immunodeficiency and MDS evolution. Penetrance and expressivity within families carrying GATA2 mutations is often variable, suggesting that co-operating extrinsic events are required to trigger the disease. Predictive tools are lacking, and intrafamilial heterogeneity is poorly understood; hence there is a clear unmet medical need. On behalf of the ERAPerMed GATA2 HuMo consortium, in this review we describe the genetic, clinical, and biological aspects of familial GATA2-related MDS, highlighting the importance of developing robust disease preclinical models to improve early detection and clinical decision-making of GATA2 carriers.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Regenerative neurology and regenerative cardiology: Shared hurdles and achievements

  • Mitrečić, Dinko
  • Hribljan, Valentina
  • Jagečić, Denis
  • Isaković, Jasmina
  • Lamberto, Federica
  • Horánszky, Alex
  • Zana, Melinda
  • Foldes, Gabor
  • Zavan, Barbara
  • Pivoriūnas, Augustas
  • Martínez, Salvador
  • Mazzini, Letizia
  • Radenovic, Lidija
  • Milasin, Jelena
  • Chachques, Juan Carlos
  • Buzanska, Leonora
  • Song, Min Suk
  • Dinnyés, András
This article belongs to the Topic Emerging Translational Research in Neurological and Psychiatric Diseases: from In Vitro to In Vivo Models., From the first success in cultivation of cells in vitro, it became clear that developing cell and/or tissue specific cultures would open a myriad of new opportunities for medical research. Expertise in various in vitro models has been developing over decades, so nowadays we benefit from highly specific in vitro systems imitating every organ of the human body. Moreover, obtaining sufficient number of standardized cells allows for cell transplantation approach with the goal of improving the regeneration of injured/disease affected tissue. However, different cell types bring different needs and place various types of hurdles on the path of regenerative neurology and regenerative cardiology. In this review, written by European experts gathered in Cost European action dedicated to neurology and cardiology-Bioneca, we present the experience acquired by working on two rather different organs: the brain and the heart. When taken into account that diseases of these two organs, mostly ischemic in their nature (stroke and heart infarction), bring by far the largest burden of the medical systems around Europe, it is not surprising that in vitro models of nervous and heart muscle tissue were in the focus of biomedical research in the last decades. In this review we describe and discuss hurdles which still impair further progress of regenerative neurology and cardiology and we detect those ones which are common to both fields and some, which are field-specific. With the goal to elucidate strategies which might be shared between regenerative neurology and cardiology we discuss methodological solutions which can help each of the fields to accelerate their development., DM research is funded by Croatian Science Foundation project Orastem (IP-16-6-9451) and by European Union through the European Regional Development Fund, as the Scientific Centre of Excellence for Basic, Clinical and Translational Neuroscience under Grant Agreement No. KK.01.1.1.01.0007, project “Experimental and clinical research of hypoxic-ischemic damage in perinatal and adult brain”. VH and DJ are supported by PhD grants by Croatian Science Foundation. LM research is partly funded by the AGING Project for Department of Excellence at the Department of Translational Medicine (DIMET), Università del Piemonte Orientale, Novara, Italy. LR and JM research is supported by Grants no 451-03-68/2020-14/200178 and no 451-03-9/2021-14/200129 of the Ministry of Education, Science and Technological Development of Republic of Serbia. GF was supported by Medical Research Council [MR/R025002/1], NIHR Imperial Biomedical Research Centre and the Hungarian National Research, Development and Innovation Fund [2020-1.1.6-JÖVŐ-2021-00013 and K128369]. A.H, F.L., A.D were supported by EU Horizon 2020 Marie Skłodowska-Curie grant agreement No 812660 (DohART-NET) and Grant Agreement No. 739593 (HCEMM) (for A.D) and Chinese-Hungarian Bilateral Project (2018-2.1.14-TÉT-CN-2018-00011, Chinese No. 8-4 (for A.D.) SM is founded by Spanish State Research Agency SAF2017-83702-R and the TERCEL (Instituto de Salud Carlos III (RD16/001/0010 and PID2020-11817RB-100). LB is supported by National Science Centre, Poland, grant # 2019/35/B/NZ3/04383., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Questioning Glutamate Excitotoxicity in Acute Brain Damage: The Importance of Spreading Depolarization

  • Andrew, R.D.
  • Farkas, E.
  • Hartings, Jed A.
  • Brennan, K. C.
  • Herreras, Óscar
  • Müller, M.
  • Kirov, S. A.
  • Ayata, C.
  • Ollen-Bittle, N.
  • Reiffurth, Clemens
  • Revah, O.
  • Robertson, R.M.
  • Dawson-Scully, K.D.
  • Ullah
  • Dreier, Jens P.
Background: Within 2 min of severe ischemia, spreading depolarization (SD) propagates like a wave through compromised gray matter of the higher brain. More SDs arise over hours in adjacent tissue, expanding the neuronal damage. This period represents a therapeutic window to inhibit SD and so reduce impending tissue injury. Yet most neuroscientists assume that the course of early brain injury can be explained by glutamate excitotoxicity, the concept that immediate glutamate release promotes early and downstream brain injury. There are many problems with glutamate release being the unseen culprit, the most practical being that the concept has yielded zero therapeutics over the past 30 years. But the basic science is also flawed, arising from dubious foundational observations beginning in the 1950s Methods: Literature pertaining to excitotoxicity and to SD over the past 60 years is critiqued. Results: Excitotoxicity theory centers on the immediate and excessive release of glutamate with resulting neuronal hyperexcitation. This instigates poststroke cascades with subsequent secondary neuronal injury. By contrast, SD theory argues that although SD evokes some brief glutamate release, acute neuronal damage and the subsequent cascade of injury to neurons are elicited by the metabolic stress of SD, not by excessive glutamate release. The challenge we present here is to find new clinical targets based on more informed basic science. This is motivated by the continuing failure by neuroscientists and by industry to develop drugs that can reduce brain injury following ischemic stroke, traumatic brain injury, or sudden cardiac arrest. One important step is to recognize that SD plays a central role in promoting early neuronal damage. We argue that uncovering the molecular biology of SD initiation and propagation is essential because ischemic neurons are usually not acutely injured unless SD propagates through them. The role of glutamate excitotoxicity theory and how it has shaped SD research is then addressed, followed by a critique of its fading relevance to the study of brain injury. Conclusions: Spreading depolarizations better account for the acute neuronal injury arising from brain ischemia than does the early and excessive release of glutamate., Grants to RDA from the Canadian Heart & Stroke Foundation, National Science Engineering and Research Council and the New Frontiers in Research Fund, to E.F from the National Research, Development and Innovation Office of Hungary, grant no. K134377; and the EU’s Horizon 2020 research and innovation program under grant agreement No. 739593, and to JPD from the DFG (German research Council) (DFG DR323/5-1,DFG DR 323/10-1) BMBF Bundesministerium fuer Bildung und Forschung (Era-Net Neuron EBio2, with funds from BMBF 01EW2004).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Questioning Glutamate Excitotoxicity in Acute Brain Damage: The Importance of Spreading Depolarization

  • Andrew, R.D.
  • Farkas, E.
  • Hartings, Jed A.
  • Brennan, K. C.
  • Herreras, Óscar
  • Müller, M.
  • Kirov, S. A.
  • Ayata, C.
  • Ollen-Bittle, N.
  • Reiffurth, Clemens
  • Revah, O.
  • Robertson, R.M.
  • Dawson-Scully, K.D.
  • Ullah
  • Dreier, Jens P.
Background: Within 2 min of severe ischemia, spreading depolarization (SD) propagates like a wave through compromised gray matter of the higher brain. More SDs arise over hours in adjacent tissue, expanding the neuronal damage. This period represents a therapeutic window to inhibit SD and so reduce impending tissue injury. Yet most neuroscientists assume that the course of early brain injury can be explained by glutamate excitotoxicity, the concept that immediate glutamate release promotes early and downstream brain injury. There are many problems with glutamate release being the unseen culprit, the most practical being that the concept has yielded zero therapeutics over the past 30 years. But the basic science is also flawed, arising from dubious foundational observations beginning in the 1950s Methods: Literature pertaining to excitotoxicity and to SD over the past 60 years is critiqued. Results: Excitotoxicity theory centers on the immediate and excessive release of glutamate with resulting neuronal hyperexcitation. This instigates poststroke cascades with subsequent secondary neuronal injury. By contrast, SD theory argues that although SD evokes some brief glutamate release, acute neuronal damage and the subsequent cascade of injury to neurons are elicited by the metabolic stress of SD, not by excessive glutamate release. The challenge we present here is to find new clinical targets based on more informed basic science. This is motivated by the continuing failure by neuroscientists and by industry to develop drugs that can reduce brain injury following ischemic stroke, traumatic brain injury, or sudden cardiac arrest. One important step is to recognize that SD plays a central role in promoting early neuronal damage. We argue that uncovering the molecular biology of SD initiation and propagation is essential because ischemic neurons are usually not acutely injured unless SD propagates through them. The role of glutamate excitotoxicity theory and how it has shaped SD research is then addressed, followed by a critique of its fading relevance to the study of brain injury. Conclusions: Spreading depolarizations better account for the acute neuronal injury arising from brain ischemia than does the early and excessive release of glutamate., Grants to RDA from the Canadian Heart & Stroke Foundation, National Science Engineering and Research Council and the New Frontiers in Research Fund, to E.F from the National Research, Development and Innovation Office of Hungary, grant no. K134377; and the EU’s Horizon 2020 research and innovation program under grant agreement No. 739593, and to JPD from the DFG (German research Council) (DFG DR323/5-1,DFG DR 323/10-1) BMBF Bundesministerium fuer Bildung und Forschung (Era-Net Neuron EBio2, with funds from BMBF 01EW2004).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

  • Mansouri, Larry
  • Thorvaldsdottir, Birna
  • Sutton, Lesley-Ann
  • Karakatsoulis, Georgios
  • Meggendorfer, Manja
  • Parker, Helen
  • Nadeu, Ferran
  • Brieghel, Christian
  • Laidou, Stamatia
  • Moia, Riccardo
  • Rossi, Davide
  • Catherwood, Mark
  • Kotaskova, Jana
  • Delgado, Julio
  • Rodríguez-Vicente, Ana Eugenia
  • Benito, Rocío
  • Rigolin, Gian Matteo
  • Bonfiglio, Silvia
  • Scarfò, Lydia
  • Mattsson, Mattias
  • Davis, Zadie
  • Gogia, Ajay
  • Rani, Lata
  • Baliakas, Panagiotis
  • Foroughi-Asl, Hassan
  • Jylhä, Cecilia
  • Skaftason, Aron
  • Rapado, Inmaculada
  • Mirás, Fátima
  • Martínez-López, Joaquín
  • Serna, Javier de la
  • De Las Rivas, Javier
  • Thornton, Patrick
  • Larráyoz, María José
  • Calasanz, Mª Jose
  • Fésüs, Viktória
  • Mátrai, Zoltán
  • Bödör, Csaba
  • Smedby, Karin E.
  • Espinet, Blanca
  • Puiggros, Anna
  • Gupta, Ritu
  • Bullinger, Lars
  • Bosch, Francesc
  • Tazón‐Vega, Bárbara
  • Baran-Marszak, Fanny
  • Oscier, David
  • Nguyen-Khac, Florence
  • Zenz, Thorsten
  • Terol, María José
  • Cuneo, Antonio
  • Hernández-Sánchez, María
  • Pospisilova, Sarka
  • Mills, Ken I.
  • Gaidano, Gianluca
  • Niemann, Carsten U.
  • Campo, Elías
  • Strefford, Jonathan C.
  • Ghia, Paolo
  • Stamatopoulos, Kostas
  • Rosenquist, Richard
Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status. In this study, we assessed the impact of nine recurrently mutated genes (BIRC3, EGR2, MYD88, NFKBIE, NOTCH1, POT1, SF3B1, TP53, and XPO1) in pre-treatment samples from 4580 patients with CLL, using time-to-first-treatment (TTFT) as the primary end-point in relation to IGHV gene SHM status. Mutations were detected in 1588 (34.7%) patients at frequencies ranging from 2.3–9.8% with mutations in NOTCH1 being the most frequent. In both univariate and multivariate analyses, mutations in all genes except MYD88 were associated with a significantly shorter TTFT. In multivariate analysis of Binet stage A patients, performed separately for IGHV-mutated (M-CLL) and unmutated CLL (U-CLL), a different spectrum of gene alterations independently predicted short TTFT within the two subgroups. While SF3B1 and XPO1 mutations were independent prognostic variables in both U-CLL and M-CLL, TP53, BIRC3 and EGR2 aberrations were significant predictors only in U-CLL, and NOTCH1 and NFKBIE only in M-CLL. Our findings underscore the need for a compartmentalized approach to identify high-risk patients, particularly among M-CLL patients, with potential implications for stratified management., This work was in part supported by; Associazione Italiana per la Ricerca sul Cancro—AIRC, Milano, Italy (Investigator Grant #20246 and Special Program on Metastatic Disease—5 per mille #21198); ERA NET TRANSCAN-2 Joint Transnational Call for Proposals: JTC 2014 (project #143 GCH-CLL) and JTC 2016 (project #179 NOVEL), project code (MIS) 5041673; Bando della Ricerca Finalizzata 2018, Ministero della Salute, Roma, Italy (progetto RF-2018–12368231); “la Caixa” Foundation (Health Research 2017 Program HR17-00221); the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245), and the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_TATA_21_3223); the Hellenic Precision Medicine Network in Oncology; project ODYSSEAS (Intelligent and Automated Systems for enabling the Design, Simulation and Development of Integrated Processes and Products) implemented under the “Action for the Strategic Development on the Research and Technological Sector”, funded by the Operational Programme “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020) and co-financed by Greece and the European Union, with grant agreement no: MIS 5002462”; MH CZ—DRO (FNBr, 65269705), NV19-03-00091 and the project National Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102)—Funded by the European Union—Next-Generation EU; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co-funded by the European Union; the EU’s Horizon 2020 research and innovation program under grant agreement No. 739593, by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the K21_137948, FK20_134253, TKP2021-EGA-24 and TKP2021-NVA-15 funding schemes, and Elixir Hungary; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co-funded by the European Union; Fondo di Ateneo per la Ricerca (FAR) 2019, 2020 and 2021 of the University of Ferrara (GMR; AC), Associazione Italiana contro le Leucemie-Linfomi e Mieloma ONLUS Ferrara (AC; GMR), BEAT Leukemia Foundation Milan Italy (AC); the Danish Cancer Society and the CLL-CLUE project under the frame of ERA PerMed; Cancer Research UK (ECRIN-M3 accelerator award C42023/A29370, Southampton Experimental Cancer Medicine Centre grant C24563/A15581, Cancer Research UK Southampton Centre grant C34999/A18087, and programme C2750/A23669); the Swedish Cancer Society (19 0425 Pj 01 H), the Swedish Research Council (2020-01750), the Knut and Alice Wallenberg Foundation (2016.0373), Region Stockholm (ALF/FoUI-962423), and Radiumhemmets Forskningsfonder (194133), Stockholm; and Lion’s Cancer Research Foundation, Uppsala., Peer reviewed
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

Transcriptome and proteome profiling reveals complex adaptations of Candida parapsilosis cells assimilating hydroxyaromatic carbon sources

  • Cillingová, Andrea
  • Tóth, Renáta
  • Mojáková, Anna
  • Zeman, Igor
  • Vrzoňová, Romana
  • Mutti, Giacomo
  • Gabaldón, Toni
Many fungal species utilize hydroxyderivatives of benzene and benzoic acid as carbon sources. The yeast Candida parapsilosis metabolizes these compounds via the 3-oxoadipate and gentisate pathways, whose components are encoded by two metabolic gene clusters. In this study, we determine the chromosome level assembly of the C. parapsilosis strain CLIB214 and use it for transcriptomic and proteomic investigation of cells cultivated on hydroxyaromatic substrates. We demonstrate that the genes coding for enzymes and plasma membrane transporters involved in the 3-oxoadipate and gentisate pathways are highly upregulated and their expression is controlled in a substrate-specific manner. However, regulatory proteins involved in this process are not known. Using the knockout mutants, we show that putative transcriptional factors encoded by the genes OTF1 and GTF1 located within these gene clusters function as transcriptional activators of the 3-oxoadipate and gentisate pathway, respectively. We also show that the activation of both pathways is accompanied by upregulation of genes for the enzymes involved in β-oxidation of fatty acids, glyoxylate cycle, amino acid metabolism, and peroxisome biogenesis. Transcriptome and proteome profiles of the cells grown on 4-hydroxybenzoate and 3-hydroxybenzoate, which are metabolized via the 3-oxoadipate and gentisate pathway, respectively, reflect their different connection to central metabolism. Yet we find that the expression profiles differ also in the cells assimilating 4-hydroxybenzoate and hydroquinone, which are both metabolized in the same pathway. This finding is consistent with the phenotype of the Otf1p-lacking mutant, which exhibits impaired growth on hydroxybenzoates, but still utilizes hydroxybenzenes, thus indicating that additional, yet unidentified transcription factor could be involved in the 3-oxoadipate pathway regulation. Moreover, we propose that bicarbonate ions resulting from decarboxylation of hydroxybenzoates also contribute to differences in the cell responses to hydroxybenzoates and hydroxybenzenes. Finally, our phylogenetic analysis highlights evolutionary paths leading to metabolic adaptations of yeast cells assimilating hydroxyaromatic substrates., This research was supported by grants from the Slovak Grant Agency (https://www.minedu.sk/vedecka-grantova-agentura-msvvas-sr-a-sav-vega/; VEGA 1/0027/19 (to J.N.), 1/0061/20 (to L.T.), 1/0136/20 (to M.N.), 1/0463/20 (to B.B.), 1/0458/18 (to T.V.)) and the Slovak Research and Development Agency (https://www.apvv.sk; APVV 18-0239 (to J.N.), APVV 19-0068 (to L.T.)). T.G. acknowledges support from the Spanish Ministry of Science and Innovation (https://council.science/member/spain-ministry-for-science-and-innovation-mcin/) for grant PGC2018-099921-B-I00, cofounded by European Regional Development Fund (ERDF). A.G. was supported by grant NKFIH K 123952 (https://nkfih.gov.hu/). The project received funding from the EU’s Horizon 2020 research and innovation program (https://ec.europa.eu/programmes/horizon2020/) under grant agreement No. 739593 (to A.G.). This study was also supported in part by the Operation Program of Integrated Infrastructure for the projects, Advancing University Capacity and Competence in Research, Development and Innovation, ITMS2014+: 313021X329, and Center for Biomedical Research - BIOMEDIRES - II. stage, ITMS2014+: 313011W428, co-financed by the European Regional Development Fund (https://ec.europa.eu/regional_policy/en/funding/erdf/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer Reviewed, "Article signat per 21 autors/es: Andrea Cillingová, Renáta Tóth, Anna Mojáková, Igor Zeman, Romana Vrzoňová, Barbara Siváková, Peter Baráth, Martina Neboháčová, Zuzana Klepcová, Filip Brázdovič, Hana Lichancová, Viktória Hodorová, Broňa Brejová, Tomáš Vinař, Sofia Mutalová, Veronika Vozáriková, Giacomo Mutti, Ľubomír Tomáška, Atilla Gácser, Toni Gabaldón, Jozef Nosek"
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Discharge protocol in acute pancreatitis: an international survey and cohort analysis

  • Nagy, Rita
  • Ocskay, Klementina
  • Sipos, Zoltán
  • Szentesi, Andrea
  • Vincze, Aron
  • Czakó, László
  • Cirera de Tudela, Arturo
  • Molero, Xavier
  • Pando, Elizabeth
  • Alberti Delgado, Piero
Discharge protocol; Acute pancreatitis, Protocol d'alta; Pancreatitis aguda, Protocolo de alta; Pancreatitis aguda, There are several overlapping clinical practice guidelines in acute pancreatitis (AP), however, none of them contains suggestions on patient discharge. The Hungarian Pancreatic Study Group (HPSG) has recently developed a laboratory data and symptom-based discharge protocol which needs to be validated. (1) A survey was conducted involving all members of the International Association of Pancreatology (IAP) to understand the characteristics of international discharge protocols. (2) We investigated the safety and effectiveness of the HPSG-discharge protocol. According to our international survey, 87.5% (49/56) of the centres had no discharge protocol. Patients discharged based on protocols have a significantly shorter median length of hospitalization (LOH) (7 (5;10) days vs. 8 (5;12) days) p < 0.001), and a lower rate of readmission due to recurrent AP episodes (p = 0.005). There was no difference in median discharge CRP level among the international cohorts (p = 0.586). HPSG-protocol resulted in the shortest LOH (6 (5;9) days) and highest median CRP (35.40 (13.78; 68.40) mg/l). Safety was confirmed by the low rate of readmittance (n = 35; 5%). Discharge protocol is necessary in AP. The discharge protocol used in this study is the first clinically proven protocol. Developing and testifying further protocols are needed to better standardize patients’ care., The study was supported by a project grant (TKP2021-EGA-23) of the Ministry of Innovation and Technology of Hungary to PH, by an NKFIH OTKA grant (K131996) to PH, by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences (to AM), by the Project Grants (KA–2019–14, FK131864 to AM) and by the ÚNKP–22–5 New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund (to AM). The project has received funding from the EU’s Horizon 2020 research and innovation program under grant agreement No. 739593. (to BCN). BCN has received funding from János Bolyai Research Grant (BO/00648/21/5) and the New National Excellence Program (UNKP-22-5-SZTE-585) and it was supported by the ÚNKP-22-4-II New national Excellence Program of the Ministry for Culture and Innovation from the Source of the National Research, Development and Innovation Fund (to KM).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Transcriptome and proteome profiling reveals complex adaptations of Candida parapsilosis cells assimilating hydroxyaromatic carbon sources

  • Cillingová, Andrea
  • Tóth, Renáta
  • Mojáková, Anna
  • Zeman, Igor
  • Vrzoňová, Romana
  • Mutti, Giacomo
  • Gabaldón, Toni
Many fungal species utilize hydroxyderivatives of benzene and benzoic acid as carbon sources. The yeast Candida parapsilosis metabolizes these compounds via the 3-oxoadipate and gentisate pathways, whose components are encoded by two metabolic gene clusters. In this study, we determine the chromosome level assembly of the C. parapsilosis strain CLIB214 and use it for transcriptomic and proteomic investigation of cells cultivated on hydroxyaromatic substrates. We demonstrate that the genes coding for enzymes and plasma membrane transporters involved in the 3-oxoadipate and gentisate pathways are highly upregulated and their expression is controlled in a substrate-specific manner. However, regulatory proteins involved in this process are not known. Using the knockout mutants, we show that putative transcriptional factors encoded by the genes OTF1 and GTF1 located within these gene clusters function as transcriptional activators of the 3-oxoadipate and gentisate pathway, respectively. We also show that the activation of both pathways is accompanied by upregulation of genes for the enzymes involved in β-oxidation of fatty acids, glyoxylate cycle, amino acid metabolism, and peroxisome biogenesis. Transcriptome and proteome profiles of the cells grown on 4-hydroxybenzoate and 3-hydroxybenzoate, which are metabolized via the 3-oxoadipate and gentisate pathway, respectively, reflect their different connection to central metabolism. Yet we find that the expression profiles differ also in the cells assimilating 4-hydroxybenzoate and hydroquinone, which are both metabolized in the same pathway. This finding is consistent with the phenotype of the Otf1p-lacking mutant, which exhibits impaired growth on hydroxybenzoates, but still utilizes hydroxybenzenes, thus indicating that additional, yet unidentified transcription factor could be involved in the 3-oxoadipate pathway regulation. Moreover, we propose that bicarbonate ions resulting from decarboxylation of hydroxybenzoates also contribute to differences in the cell responses to hydroxybenzoates and hydroxybenzenes. Finally, our phylogenetic analysis highlights evolutionary paths leading to metabolic adaptations of yeast cells assimilating hydroxyaromatic substrates., This research was supported by grants from the Slovak Grant Agency (https://www.minedu.sk/vedecka-grantova-agentura-msvvas-sr-a-sav-vega/; VEGA 1/0027/19 (to J.N.), 1/0061/20 (to L.T.), 1/0136/20 (to M.N.), 1/0463/20 (to B.B.), 1/0458/18 (to T.V.)) and the Slovak Research and Development Agency (https://www.apvv.sk; APVV 18-0239 (to J.N.), APVV 19-0068 (to L.T.)). T.G. acknowledges support from the Spanish Ministry of Science and Innovation (https://council.science/member/spain-ministry-for-science-and-innovation-mcin/) for grant PGC2018-099921-B-I00, cofounded by European Regional Development Fund (ERDF). A.G. was supported by grant NKFIH K 123952 (https://nkfih.gov.hu/). The project received funding from the EU’s Horizon 2020 research and innovation program (https://ec.europa.eu/programmes/horizon2020/) under grant agreement No. 739593 (to A.G.). This study was also supported in part by the Operation Program of Integrated Infrastructure for the projects, Advancing University Capacity and Competence in Research, Development and Innovation, ITMS2014+: 313021X329, and Center for Biomedical Research - BIOMEDIRES - II. stage, ITMS2014+: 313011W428, co-financed by the European Regional Development Fund (https://ec.europa.eu/regional_policy/en/funding/erdf/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer Reviewed, "Article signat per 21 autors/es: Andrea Cillingová, Renáta Tóth, Anna Mojáková, Igor Zeman, Romana Vrzoňová, Barbara Siváková, Peter Baráth, Martina Neboháčová, Zuzana Klepcová, Filip Brázdovič, Hana Lichancová, Viktória Hodorová, Broňa Brejová, Tomáš Vinař, Sofia Mutalová, Veronika Vozáriková, Giacomo Mutti, Ľubomír Tomáška, Atilla Gácser, Toni Gabaldón, Jozef Nosek", Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

  • Mansouri, Larry
  • Thorvaldsdottir, Birna
  • Sutton, Lesley-Ann
  • KARAKATSOULIS, GEORGIOS
  • Meggendorfer, Manja
  • Parker, Helen
  • Tazon-Vega, Barbara
  • Bosch, Francesc
Cancer genetics; Genetics research, Genètica del càncer; Recerca genètica, Genética del cáncer; Investigación genética, Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status. In this study, we assessed the impact of nine recurrently mutated genes (BIRC3, EGR2, MYD88, NFKBIE, NOTCH1, POT1, SF3B1, TP53, and XPO1) in pre-treatment samples from 4580 patients with CLL, using time-to-first-treatment (TTFT) as the primary end-point in relation to IGHV gene SHM status. Mutations were detected in 1588 (34.7%) patients at frequencies ranging from 2.3–9.8% with mutations in NOTCH1 being the most frequent. In both univariate and multivariate analyses, mutations in all genes except MYD88 were associated with a significantly shorter TTFT. In multivariate analysis of Binet stage A patients, performed separately for IGHV-mutated (M-CLL) and unmutated CLL (U-CLL), a different spectrum of gene alterations independently predicted short TTFT within the two subgroups. While SF3B1 and XPO1 mutations were independent prognostic variables in both U-CLL and M-CLL, TP53, BIRC3 and EGR2 aberrations were significant predictors only in U-CLL, and NOTCH1 and NFKBIE only in M-CLL. Our findings underscore the need for a compartmentalized approach to identify high-risk patients, particularly among M-CLL patients, with potential implications for stratified management., The European Research Initiative on CLL (ERIC) is a partner in the HARMONY Alliance, the EHA Scientific Working group on CLL and the ELN Workpackage 7 on CLL. This work was in part supported by; Associazione Italiana per la Ricerca sul Cancro—AIRC, Milano, Italy (Investigator Grant #20246 and Special Program on Metastatic Disease—5 per mille #21198); ERA NET TRANSCAN-2 Joint Transnational Call for Proposals: JTC 2014 (project #143 GCH-CLL) and JTC 2016 (project #179 NOVEL), project code (MIS) 5041673; Bando della Ricerca Finalizzata 2018, Ministero della Salute, Roma, Italy (progetto RF-2018–12368231); “la Caixa” Foundation (Health Research 2017 Program HR17-00221); the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245), and the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_TATA_21_3223); the Hellenic Precision Medicine Network in Oncology; project ODYSSEAS (Intelligent and Automated Systems for enabling the Design, Simulation and Development of Integrated Processes and Products) implemented under the “Action for the Strategic Development on the Research and Technological Sector”, funded by the Operational Programme “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020) and co-financed by Greece and the European Union, with grant agreement no: MIS 5002462”; MH CZ—DRO (FNBr, 65269705), NV19-03-00091 and the project National Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102)—Funded by the European Union—Next-Generation EU; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co-funded by the European Union; the EU’s Horizon 2020 research and innovation program under grant agreement No. 739593, by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the K21_137948, FK20_134253, TKP2021-EGA-24 and TKP2021-NVA-15 funding schemes, and Elixir Hungary; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co-funded by the European Union; Fondo di Ateneo per la Ricerca (FAR) 2019, 2020 and 2021 of the University of Ferrara (GMR; AC), Associazione Italiana contro le Leucemie-Linfomi e Mieloma ONLUS Ferrara (AC; GMR), BEAT Leukemia Foundation Milan Italy (AC); the Danish Cancer Society and the CLL-CLUE project under the frame of ERA PerMed; Cancer Research UK (ECRIN-M3 accelerator award C42023/A29370, Southampton Experimental Cancer Medicine Centre grant C24563/A15581, Cancer Research UK Southampton Centre grant C34999/A18087, and programme C2750/A23669); the Swedish Cancer Society (19 0425 Pj 01 H), the Swedish Research Council (2020-01750), the Knut and Alice Wallenberg Foundation (2016.0373), Region Stockholm (ALF/FoUI-962423), and Radiumhemmets Forskningsfonder (194133), Stockholm; and Lion’s Cancer Research Foundation, Uppsala.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

GATA2 deficiency and MDS/AML: experimental strategies for disease modelling and future therapeutic prospects

  • Kotmayer, Lili
  • Romero Moya, Damià
  • Marin-Bejar, Oskar
  • Kozyra, Emilia
  • Català, Albert
  • Bigas Salvans, Anna
  • Wlodarski, Marcin W
  • Bödör, Csaba
  • Giorgetti, Alessandra
The importance of predisposition to leukaemia in clinical practice is being increasingly recognized. This is emphasized by the establishment of a novel WHO disease category in 2016 called 'myeloid neoplasms with germline predisposition'. A major syndrome within this group is GATA2 deficiency, a heterogeneous immunodeficiency syndrome with a very high lifetime risk to develop myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). GATA2 deficiency has been identified as the most common hereditary cause of MDS in adolescents with monosomy 7. Allogenic haematopoietic stem cell transplantation is the only curative option; however, chances of survival decrease with progression of immunodeficiency and MDS evolution. Penetrance and expressivity within families carrying GATA2 mutations is often variable, suggesting that co-operating extrinsic events are required to trigger the disease. Predictive tools are lacking, and intrafamilial heterogeneity is poorly understood; hence there is a clear unmet medical need. On behalf of the ERAPerMed GATA2 HuMo consortium, in this review we describe the genetic, clinical, and biological aspects of familial GATA2-related MDS, highlighting the importance of developing robust disease preclinical models to improve early detection and clinical decision-making of GATA2 carriers.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: A study by ERIC in HARMONY

  • Mansouri, Larry
  • Espinet Solà, Blanca
  • Rosenquist, Richard
Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status. In this study, we assessed the impact of nine recurrently mutated genes (BIRC3, EGR2, MYD88, NFKBIE, NOTCH1, POT1, SF3B1, TP53, and XPO1) in pre-treatment samples from 4580 patients with CLL, using time-to-first-treatment (TTFT) as the primary end-point in relation to IGHV gene SHM status. Mutations were detected in 1588 (34.7%) patients at frequencies ranging from 2.3-9.8% with mutations in NOTCH1 being the most frequent. In both univariate and multivariate analyses, mutations in all genes except MYD88 were associated with a significantly shorter TTFT. In multivariate analysis of Binet stage A patients, performed separately for IGHV-mutated (M-CLL) and unmutated CLL (U-CLL), a different spectrum of gene alterations independently predicted short TTFT within the two subgroups. While SF3B1 and XPO1 mutations were independent prognostic variables in both U-CLL and M-CLL, TP53, BIRC3 and EGR2 aberrations were significant predictors only in U-CLL, and NOTCH1 and NFKBIE only in M-CLL. Our findings underscore the need for a compartmentalized approach to identify high-risk patients, particularly among M-CLL patients, with potential implications for stratified management., The European Research Initiative on CLL (ERIC) is a partner in the HARMONY Alliance, the EHA Scientific Working group on CLL and the ELN Workpackage 7 on CLL. This work was in part supported by; Associazione Italiana per la Ricerca sul Cancro—AIRC, Milano, Italy (Investigator Grant #20246 and Special Program on Metastatic Disease—5 per mille #21198); ERA NET TRANSCAN-2 Joint Transnational Call for Proposals: JTC 2014 (project #143 GCH-CLL) and JTC 2016 (project #179 NOVEL), project code (MIS) 5041673; Bando della Ricerca Finalizzata 2018, Ministero della Salute, Roma, Italy (progetto RF-2018–12368231); “la Caixa” Foundation (Health Research 2017 Program HR17-00221); the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245), and the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_TATA_21_3223); the Hellenic Precision Medicine Network in Oncology; project ODYSSEAS (Intelligent and Automated Systems for enabling the Design, Simulation and Development of Integrated Processes and Products) implemented under the “Action for the Strategic Development on the Research and Technological Sector”, funded by the Operational Programme “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020) and co-financed by Greece and the European Union, with grant agreement no: MIS 5002462”; MH CZ—DRO (FNBr, 65269705), NV19-03-00091 and the project National Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102)—Funded by the European Union—Next-Generation EU; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co-funded by the European Union; the EU’s Horizon 2020 research and innovation program under grant agreement No. 739593, by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the K21_137948, FK20_134253, TKP2021-EGA-24 and TKP2021-NVA-15 funding schemes, and Elixir Hungary; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co-funded by the European Union; Fondo di Ateneo per la Ricerca (FAR) 2019, 2020 and 2021 of the University of Ferrara (GMR; AC), Associazione Italiana contro le Leucemie-Linfomi e Mieloma ONLUS Ferrara (AC; GMR), BEAT Leukemia Foundation Milan Italy (AC); the Danish Cancer Society and the CLL-CLUE project under the frame of ERA PerMed; Cancer Research UK (ECRIN-M3 accelerator award C42023/A29370, Southampton Experimental Cancer Medicine Centre grant C24563/A15581, Cancer Research UK Southampton Centre grant C34999/A18087, and programme C2750/A23669); the Swedish Cancer Society (19 0425 Pj 01 H), the Swedish Research Council (2020-01750), the Knut and Alice Wallenberg Foundation (2016.0373), Region Stockholm (ALF/FoUI-962423), and Radiumhemmets Forskningsfonder (194133), Stockholm; and Lion’s Cancer Research Foundation, Uppsala.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

GATA2 deficiency and MDS/AML: experimental strategies for disease modelling and future therapeutic prospects

  • Kotmayer, Lili
  • Romero-Moya, Damià
  • Marin-Bejar, Oskar
  • Kozyra, Emilia
  • Català, Albert
  • Bigas Salvans, Anna
  • Wlodarski, Marcin W.
  • Bödör, Csaba
  • Giorgetti, Alessandra
The importance of predisposition to leukaemia in clinical practice is being increasingly recognized. This is emphasized by the establishment of a novel WHO disease category in 2016 called "myeloid neoplasms with germline predisposition". A major syndrome within this group is GATA2 deficiency, a heterogeneous immunodeficiency syndrome with a very high lifetime risk to develop myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). GATA2 deficiency has been identified as the most common hereditary cause of MDS in adolescents with monosomy 7. Allogenic haematopoietic stem cell transplantation is the only curative option; however, chances of survival decrease with progression of immunodeficiency and MDS evolution. Penetrance and expressivity within families carrying GATA2 mutations is often variable, suggesting that co-operating extrinsic events are required to trigger the disease. Predictive tools are lacking, and intrafamilial heterogeneity is poorly understood; hence there is a clear unmet medical need. On behalf of the ERAPerMed GATA2 HuMo consortium, in this review we describe the genetic, clinical, and biological aspects of familial GATA2-related MDS, highlighting the importance of developing robust disease preclinical models to improve early detection and clinical decision-making of GATA2 carriers., This work was supported by ERA PerMed GATA2-HuMo Funding Mechanism (Spain: Acció instrumental de SLT011/18/00006 of the Department of Health of the Government of Catalonia, to AG and AB; Hungary: ED-18-1-2019-001 grant from the National Research, Development and Innovation Office to CB; and Germany: German Federal Ministry of Education and Research (BMBF) 2018-123/01KU1904 to MWW), ÚNKP-21-2-I-SE-21 and Hungarian National Academy of Scientist Education grant to KL, TKP2021-NVA-15, TKP2021-EGA-24 and EU's Horizon 2020 research and innovation programme under grant agreement no. 739593 and Elixir Hungary to CB, MSCA No 101029927-scGATA2track (H2020-MSCA-IF-2020) to OM-B, the Spanish Ministry of Economy, Industry, and Competitiveness (MINECO PID2020-15591RB-100), La Marató de TV3 (202001-32), FPS Grant 2018 by Fondazione Pisana per la Scienza ONLUS and CERCA Programme/Generalitat de Catalunya for institutional support to AG, Vera and Joseph Dresner Foundation, Evans MDS Foundation, American Lebanese Syrian Associated Charities, and BMBF MyPred 01GM1911A to MWW. Open access funding enabled and organized by ProjektDEAL.
Docta Complutense
Publication Artículo científico (JournalArticle)

The Role of P2X7 Receptor in Alzheimer’s Disease

  • Francistiová, Linda
  • Bianchi, Carolina
  • Di Lauro, Caterina
  • Sebastián Serrano, Álvaro
  • De Diego García, Laura
  • Kobolák, Julianna
  • Dinnyés, András
  • Díaz Hernández, Miguel
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease characterized by a progressive cognitive decline associated with global brain damage. Initially, intracellular paired helical filaments composed by hyperphosphorylated tau and extracellular deposits of amyloid-b (Ab) were postulated as the causing factors of the synaptic dysfunction, neuroinflammation, oxidative stress, and neuronal death, detected in AD patients. Therefore, the vast majority of clinical trials were focused on targeting Ab and tau directly, but no effective treatment has been reported so far. Consequently, only palliative treatments are currently available for AD patients. Over recent years, several studies have suggested the involvement of the purinergic receptor P2X7 (P2X7R), a plasma membrane ionotropic ATP-gated receptor, in the AD brain pathology. In this line, altered expression levels and function of P2X7R were found both in AD patients and AD mouse models. Consequently, genetic depletion or pharmacological inhibition of P2X7R ameliorated the hallmarks and symptoms of different AD mouse models. In this review, we provide an overview of the current knowledge about the role of the P2X7R in AD.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

PCSK9 in Myocardial Infarction and Cardioprotection, Importance of Lipid Metabolism and Inflammation

  • Andreadou, Ioanna
  • Tsoumani, Maria
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Ikonomidis, Ignatios
  • Badimon, Lina|||0000-0002-9162-2459
  • Varga, Zoltán V.
  • Ferdinandy, Péter|||0000-0002-6424-6806
  • Schulz, Rainer
Extensive evidence from epidemiologic, genetic, and clinical intervention studies has indisputably shown that elevated low-density lipoprotein cholesterol (LDL-C) concentrations play a central role in the pathophysiology of atherosclerotic cardiovascular disease. Apart from LDL-C, also triglycerides independently modulate cardiovascular risk. Reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma LDL-C, but it is also associated with a reduction in triglyceride levels potentially through modulation of the expression of free fatty acid transporters. Preclinical data indicate that PCSK9 is up-regulated in the ischaemic heart and decreasing PCSK9 expression impacts on infarct size, post infarct inflammation and remodeling as well as cardiac dysfunction following ischaemia/reperfusion. Clinical data support that notion in that PCSK9 inhibition is associated with reductions in the incidence of myocardial infarction, stroke, and coronary revascularization and an improvement of endothelial function in subjects with increased cardiovascular risk. The aim of the current review is to summarize the current knowledge on the importance of free fatty acid metabolism on myocardial ischaemia/reperfusion injury and to provide an update on recent evidence on the role of hyperlipidemia and PCSK9 in myocardial infarction and cardioprotection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

GATA2 deficiency and MDS/AML, Experimental strategies for disease modelling and future therapeutic prospects

  • Kotmayer, Lili|||0000-0002-5089-7659
  • Romero Moya, Damià|||0000-0001-9947-3577
  • Marin-Béjar, Oskar|||0000-0002-6889-6566
  • Kozyra, Emilia|||0000-0003-1107-8818
  • Català, Albert|||0000-0003-0133-1752
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Wlodarski, Marcin W.|||0000-0001-6638-9643
  • Bödör, Csaba|||0000-0002-0729-692X
  • Giorgetti, Alessandra|||0000-0001-5803-3567
The importance of predisposition to leukaemia in clinical practice is being increasingly recognized. This is emphasized by the establishment of a novel WHO disease category in 2016 called "myeloid neoplasms with germline predisposition". A major syndrome within this group is GATA2 deficiency, a heterogeneous immunodeficiency syndrome with a very high lifetime risk to develop myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). GATA2 deficiency has been identified as the most common hereditary cause of MDS in adolescents with monosomy 7. Allogenic haematopoietic stem cell transplantation is the only curative option; however, chances of survival decrease with progression of immunodeficiency and MDS evolution. Penetrance and expressivity within families carrying GATA2 mutations is often variable, suggesting that co-operating extrinsic events are required to trigger the disease. Predictive tools are lacking, and intrafamilial heterogeneity is poorly understood; hence there is a clear unmet medical need. On behalf of the ERAPerMed GATA2 HuMo consortium, in this review we describe the genetic, clinical, and biological aspects of familial GATA2-related MDS, highlighting the importance of developing robust disease preclinical models to improve early detection and clinical decision-making of GATA2 carriers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency

  • Marin-Bejar, Oskar
  • Romero Moya, Damià|||0000-0001-9947-3577
  • Rodriguez-Ubreva, Javier
  • Distefano, Maximiliano
  • Lessi, Francesca
  • Aretini, Paolo|||0000-0003-1075-4319
  • Liquori, Alessandro|||0000-0002-4842-5986
  • Castaño Cardoso, Julio|||0000-0002-0712-5856
  • Kozyra, Emilia|||0000-0003-1107-8818
  • Kotmayer, Lili|||0000-0002-5089-7659
  • Bueno, Clara|||0000-0003-1442-6216
  • Cervera, José|||0000-0001-8252-1106
  • Rodriguez-Gallego, José Carlos
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Murillo- Sanjuán, Laura
  • de Heredia, Cristina Díaz
  • Pérez-Martinez, Antonio
  • López-Cadenas, Félix
  • Martínez-Laperche, Carolina
  • Dorado-Herrero, Nieves
  • Marco, Francisco M.
  • Prósper, Felipe
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Valcárcel, David|||0000-0002-8747-078X
  • Ballestar, Esteban|||0000-0002-1400-2440
  • Bödör, Csaba|||0000-0002-0729-692X
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Català, Albert|||0000-0003-0133-1752
  • Wlodarski, Marcin W.|||0000-0001-6638-9643
  • Giorgetti, Alessandra|||0000-0001-5803-3567
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Discharge protocol in acute pancreatitis: an international survey and cohort analysis

  • Nagy, Rita
  • Ocskay, Klementina
  • Sipos, Zoltán
  • Szentesi, Andrea
  • Vincze, Aron
  • Czakó, László
  • Cirera de Tudela, Arturo
  • Molero, Xavier
  • Pando, Elizabeth
  • Alberti Delgado, Piero
Discharge protocol; Acute pancreatitis, Protocol d'alta; Pancreatitis aguda, Protocolo de alta; Pancreatitis aguda, There are several overlapping clinical practice guidelines in acute pancreatitis (AP), however, none of them contains suggestions on patient discharge. The Hungarian Pancreatic Study Group (HPSG) has recently developed a laboratory data and symptom-based discharge protocol which needs to be validated. (1) A survey was conducted involving all members of the International Association of Pancreatology (IAP) to understand the characteristics of international discharge protocols. (2) We investigated the safety and effectiveness of the HPSG-discharge protocol. According to our international survey, 87.5% (49/56) of the centres had no discharge protocol. Patients discharged based on protocols have a significantly shorter median length of hospitalization (LOH) (7 (5;10) days vs. 8 (5;12) days) p < 0.001), and a lower rate of readmission due to recurrent AP episodes (p = 0.005). There was no difference in median discharge CRP level among the international cohorts (p = 0.586). HPSG-protocol resulted in the shortest LOH (6 (5;9) days) and highest median CRP (35.40 (13.78; 68.40) mg/l). Safety was confirmed by the low rate of readmittance (n = 35; 5%). Discharge protocol is necessary in AP. The discharge protocol used in this study is the first clinically proven protocol. Developing and testifying further protocols are needed to better standardize patients’ care., The study was supported by a project grant (TKP2021-EGA-23) of the Ministry of Innovation and Technology of Hungary to PH, by an NKFIH OTKA grant (K131996) to PH, by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences (to AM), by the Project Grants (KA–2019–14, FK131864 to AM) and by the ÚNKP–22–5 New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund (to AM). The project has received funding from the EU’s Horizon 2020 research and innovation program under grant agreement No. 739593. (to BCN). BCN has received funding from János Bolyai Research Grant (BO/00648/21/5) and the New National Excellence Program (UNKP-22-5-SZTE-585) and it was supported by the ÚNKP-22-4-II New national Excellence Program of the Ministry for Culture and Innovation from the Source of the National Research, Development and Innovation Fund (to KM).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

  • Mansouri, Larry
  • Thorvaldsdottir, Birna
  • Sutton, Lesley-Ann
  • KARAKATSOULIS, GEORGIOS
  • Meggendorfer, Manja
  • Parker, Helen
  • Tazon-Vega, Barbara
  • Bosch, Francesc
Cancer genetics; Genetics research, Genètica del càncer; Recerca genètica, Genética del cáncer; Investigación genética, Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status. In this study, we assessed the impact of nine recurrently mutated genes (BIRC3, EGR2, MYD88, NFKBIE, NOTCH1, POT1, SF3B1, TP53, and XPO1) in pre-treatment samples from 4580 patients with CLL, using time-to-first-treatment (TTFT) as the primary end-point in relation to IGHV gene SHM status. Mutations were detected in 1588 (34.7%) patients at frequencies ranging from 2.3–9.8% with mutations in NOTCH1 being the most frequent. In both univariate and multivariate analyses, mutations in all genes except MYD88 were associated with a significantly shorter TTFT. In multivariate analysis of Binet stage A patients, performed separately for IGHV-mutated (M-CLL) and unmutated CLL (U-CLL), a different spectrum of gene alterations independently predicted short TTFT within the two subgroups. While SF3B1 and XPO1 mutations were independent prognostic variables in both U-CLL and M-CLL, TP53, BIRC3 and EGR2 aberrations were significant predictors only in U-CLL, and NOTCH1 and NFKBIE only in M-CLL. Our findings underscore the need for a compartmentalized approach to identify high-risk patients, particularly among M-CLL patients, with potential implications for stratified management., The European Research Initiative on CLL (ERIC) is a partner in the HARMONY Alliance, the EHA Scientific Working group on CLL and the ELN Workpackage 7 on CLL. This work was in part supported by; Associazione Italiana per la Ricerca sul Cancro—AIRC, Milano, Italy (Investigator Grant #20246 and Special Program on Metastatic Disease—5 per mille #21198); ERA NET TRANSCAN-2 Joint Transnational Call for Proposals: JTC 2014 (project #143 GCH-CLL) and JTC 2016 (project #179 NOVEL), project code (MIS) 5041673; Bando della Ricerca Finalizzata 2018, Ministero della Salute, Roma, Italy (progetto RF-2018–12368231); “la Caixa” Foundation (Health Research 2017 Program HR17-00221); the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245), and the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_TATA_21_3223); the Hellenic Precision Medicine Network in Oncology; project ODYSSEAS (Intelligent and Automated Systems for enabling the Design, Simulation and Development of Integrated Processes and Products) implemented under the “Action for the Strategic Development on the Research and Technological Sector”, funded by the Operational Programme “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020) and co-financed by Greece and the European Union, with grant agreement no: MIS 5002462”; MH CZ—DRO (FNBr, 65269705), NV19-03-00091 and the project National Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102)—Funded by the European Union—Next-Generation EU; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co-funded by the European Union; the EU’s Horizon 2020 research and innovation program under grant agreement No. 739593, by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the K21_137948, FK20_134253, TKP2021-EGA-24 and TKP2021-NVA-15 funding schemes, and Elixir Hungary; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co-funded by the European Union; Fondo di Ateneo per la Ricerca (FAR) 2019, 2020 and 2021 of the University of Ferrara (GMR; AC), Associazione Italiana contro le Leucemie-Linfomi e Mieloma ONLUS Ferrara (AC; GMR), BEAT Leukemia Foundation Milan Italy (AC); the Danish Cancer Society and the CLL-CLUE project under the frame of ERA PerMed; Cancer Research UK (ECRIN-M3 accelerator award C42023/A29370, Southampton Experimental Cancer Medicine Centre grant C24563/A15581, Cancer Research UK Southampton Centre grant C34999/A18087, and programme C2750/A23669); the Swedish Cancer Society (19 0425 Pj 01 H), the Swedish Research Council (2020-01750), the Knut and Alice Wallenberg Foundation (2016.0373), Region Stockholm (ALF/FoUI-962423), and Radiumhemmets Forskningsfonder (194133), Stockholm; and Lion’s Cancer Research Foundation, Uppsala.